Skip to content

Evaluation of the Effect of Methylene Blue in the Treatment of Outpatients with COVID-19 Referred to the Lung Clinic

Evaluation of the Effect of Methylene Blue with Supplements in the Treatment of Patients with Moderate to Severe Outpatient COVID-19 Infection in Comparison with the Control Group

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220211053993N1
Enrollment
240
Registered
2022-05-28
Start date
2022-06-22
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Covid-19

Interventions

Intervention 1: Intervention group: In addition to the standard treatment, Covid-19 outpatients are received orally methylene blue along with complementary materials two times per day in interval tim

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Outpatients with COVID-19 virus referred to a Lung Clinic Confirmed by HRCT or PCR SPO2 without Mask after Ten Minutes between 70-96 Age Over 18 Years Old

Exclusion criteria

Exclusion criteria: Pregnancy Severe Liver and Heart Disease Acute Renal Failure Associated with the Need for Dialysis Glucose 6-Phosphate Dehydrogenase Deficiency

Design outcomes

Primary

MeasureTime frame
Oxygen pressure saturation. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Pulse oximeter.;Respiratory Rate. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Headache. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Cough. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Shivery. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Chest pain. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Vomiting. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Diarrhea. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.;Fever. Timepoint: Interval time: the third day, the sixth day, the eleventh day, the fourteenth day after using Methylene Blue. Method of measurement: Physical exam.

Secondary

MeasureTime frame
Hospital stay time. Timepoint: After 15 days. Method of measurement: Number of days.;Mortality rate. Timepoint: After 30 days. Method of measurement: Review of medical records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Davood Attaran

Mashhad University of Medical Sciences

attarand@mums.ac.ir+98 51 3833 2746

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026